Pages

▼
Showing posts with label American Association for Cancer Research. Show all posts
Showing posts with label American Association for Cancer Research. Show all posts
March 5, 2014

"...systemic immunity induced by PV-10 tumor ablation"

›
An abstract of Moffitt Cancer Center's work, led I think by  Dr. Amod Sarnaik, MD, a surgical oncologist , and Dr. Shari Pilon-Thomas,...
February 21, 2014

It's all about the T-cells

›
I'm looking forward to reading Moffitt Cancer Center's American Association for Cancer Research ("AACR") annual meeting ab...
May 7, 2013

Explaining @MoffittNews' #AACR2013's Abstract for $PVCT's PV-10

›
A blog reader sent me the following "translation" of Moffitt's AACR abstract. Thank you. Presentation Title:  Intralesional...
April 14, 2013

$PVCT: Post-AACR...

›
What now? AACR is finished. Two posters displayed: Moffitt and Provectus . Moffit's poster presentation displayed definitive data on PV...
April 11, 2013

$PVCT: And Dr. Eric Wachter commented...

›
Eric's responsibility at Provectus comprises clinical development (e.g., trials, biostats, regulatory affairs, etc.), manufacturing and ...

$PVCT: London Calling (where else, @starbucks)

›
My students are doing what they need to do, effectively telling me they don't need me or need me around. I have more time on my hands th...
April 10, 2013

$PVCT: PV-10 Data Presented by Moffitt Cancer Center Researchers Examines Induction of Systemic Immune Response in Multiple Tumor Types

›
Provectus issued a PR to circulate Moffitt's AACR poster. The poster is here . It is worthwhile to focus on Moffitt's Dr. Pilon-Tho...
April 8, 2013

$PVCT Should Provide Moffitt Poster Once AACR ends

›
I would imagine because of AACR conference stipulations or regulations, Moffitt's poster will be made available when or after the confer...

@MoffittNews & $PVCT at #AACR: PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the American Association for Cancer Research Annual Meeting

›
Provectus issued a PR today about Moffitt's poster presentation. Dr. Pilon-Thomas commented, “We believe our findings are meaningful b...
April 5, 2013

More Serious #Pharma Interest in $PVCT

›
At his presentation in New York in March, Craig noted Provectus was in the due diligence process of a pharmaceutical company for a global l...
March 30, 2013

$PVCT at #AACR

›
Provectus' approach to AACR PR will be to focus awareness of PV-10 from both investigator and advocate perspectives.
March 14, 2013

$PVCT & Breakthrough Therapy Designation (update)

›
It appears management will indeed consider submitting a request for breakthrough therapy designation to the FDA for PV-10, starting with met...
March 13, 2013

$PVCT & Breakthrough Therapy Designation

›
A friend of the blog provided this link from the FDA's website: FAQs about the designation . Thank you. Updated statistics about applica...
March 6, 2013

$PVCT #AACR2013 Thoughts...

›
Two summary thoughts from today's release of the AACR abstracts, one by Moffitt and one by Provectus, follow. Moffitt The first one d...

$PVCT #AACR2013: Combination of PV-10 immuno-chemoablation and systemic anti-CTLA-4 antibody therapy in murine models of #melanoma

›
Presentation Title: Combination of PV-10 immuno-chemoablation and systemic anti-CTLA-4 antibody therapy in murine models of melanoma Abst...

$PVCT -- @MoffittNews #AACR2013: Intralesional injection with PV-10 induces a systemic anti-tumor immune response in murine models of #breast #cancer and #melanoma

›
Presentation Title:  Intralesional injection with PV-10 induces a systemic anti-tumor immune response in murine models of breast cancer and ...
March 1, 2013

$PVCT -- @MoffittNews #AACR2013: Intralesional injection with PV-10 induces a systemic anti-tumor immune response in murine models of #breast #cancer and #melanoma

›
A Moffitt poster presentation at AACR in April: Intralesional injection with PV-10 induces a systemic anti-tumor immune response in murine m...
February 28, 2013

$PVCT: The #Holy #Grail of #Cancer Treatment is...

›
It was interesting to read about Moffitt's work in the February edition of Cancer Watch . Some believe Provectus has the most unusua...
January 24, 2013

$PVCT: Provectus to Present Data on PV-10 at the American Association for Cancer Research Annual Meeting in April 2013

›
Provectus issued a PR yesterday  announcing the acceptance of Craig et al.'s poster presentation -- Combination of PV-10 immuno-chemoabl...